Description:

CALGB: 80802 Follow-Up and Response Form Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=741A9174-BCA1-70FC-E040-BB89AD436A0F

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=741A9174-BCA1-70FC-E040-BB89AD436A0F
Keywords:
  1. 9/19/12 9/19/12 -
  2. 1/8/15 1/8/15 - Martin Dugas
Uploaded on:

January 8, 2015

DOI:
To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Liver Cancer NCT01015833 Response - CALGB: 80802 Follow-Up and Response Form - 2943577v1.0

INSTRUCTIONS: Complete and submit this form as required by the protocol. Information in the upper right box must be completed for this form to be accepted.

Header
Are data amended
Unnamed2
Unnamed Module 3
Vital status (Mark one with an X.)
Primary Cause of Death (Mark one with an X.)
Response Data
Best response since beginning protocol therapy (Mark one with an X.)
Sites of Progression (Mark all that apply with an X.)
Is the patient receiving any non-protocol cancer therapy not previously reported?
Footer

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial